Compare Incyte Corporation (INCY) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Incyte Corporation trades at $117.54 (market cap $23.11B), while iShares 20 Plus Year Treasury Bond ETF trades at $83.69. The key difference: Incyte Corporation is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| INCY | TLT | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | — |
52-Week High | $118.52 | $92.06 |
52-Week Low | $67.38 | $83.02 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $83.89, down 0.75% on the day. Technical indicators signal a bearish trend with moving averages showing selling pressure, while oscillators are neutral. The ETF has faced significant outflows amid rising interest rate concerns, with recent articles highlighting competition from cash ETFs and corporate bond alternatives offering higher yields. Dividend payments remain consistent but modest.
The outlook for TLT hinges on Federal Reserve policy shifts; potential rate cuts could boost long-term bonds, but persistent inflation risks may extend volatility. Investors face duration risk and opportunity cost versus shorter-term instruments. Wall Street sentiment is mixed, with some seeing value at current yields after steep declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
